302 related articles for article (PubMed ID: 18559873)
21. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
[TBL] [Abstract][Full Text] [Related]
22. Haematopoietic growth factors in the treatment of myelodysplastic syndromes.
Cazzola M
Forum (Genova); 1999; 9(1):49-57. PubMed ID: 10101210
[TBL] [Abstract][Full Text] [Related]
23. Revisiting use of growth factors in myelodysplastic syndromes.
Newman K; Maness-Harris L; El-Hemaidi I; Akhtari M
Asian Pac J Cancer Prev; 2012; 13(4):1081-91. PubMed ID: 22799286
[TBL] [Abstract][Full Text] [Related]
24. Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes.
Geissler RG; Schulte P; Ganser A
Int J Hematol; 1997 Jun; 65(4):339-54. PubMed ID: 9195774
[TBL] [Abstract][Full Text] [Related]
25. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model.
Hellström-Lindberg E; Negrin R; Stein R; Krantz S; Lindberg G; Vardiman J; Ost A; Greenberg P
Br J Haematol; 1997 Nov; 99(2):344-51. PubMed ID: 9375752
[TBL] [Abstract][Full Text] [Related]
26. Erythropoiesis stimulating agents and other growth factors in low-risk MDS.
Hellström-Lindberg E; van de Loosdrecht A
Best Pract Res Clin Haematol; 2013 Dec; 26(4):401-10. PubMed ID: 24507816
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys.
Sekeres MA; Schoonen WM; Kantarjian H; List A; Fryzek J; Paquette R; Maciejewski JP
J Natl Cancer Inst; 2008 Nov; 100(21):1542-51. PubMed ID: 18957672
[TBL] [Abstract][Full Text] [Related]
28. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
[TBL] [Abstract][Full Text] [Related]
29. [Effect of recombinant human G-CSF combined with EPO in treatment of patients with MDS].
Li ZY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):512-3. PubMed ID: 15972155
[TBL] [Abstract][Full Text] [Related]
30. A hematological remission by clonal hematopoiesis after treatment with recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin in a patient with therapy-related myelodysplastic syndrome.
Bessho M; Itoh Y; Kataumi S; Kawai N; Matsuda A; Jinnai I; Saitoh M; Hirashima K; Minamihisamatsu M
Leuk Res; 1992; 16(2):123-31. PubMed ID: 1545564
[TBL] [Abstract][Full Text] [Related]
31. In vitro stimulation of erythropoiesis by stem cell factor alone in myelodysplastic syndrome patients with elevated endogenous erythropoietin serum levels.
Zwierzina H; Bammer T; Rollinger-Holzinger I; Herold M; Fenaux P; Nüssler V; Hoflehner E; Geissler D
Clin Cancer Res; 1996 Jun; 2(6):1031-8. PubMed ID: 9816264
[TBL] [Abstract][Full Text] [Related]
32. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
33. Sequential administration of recombinant human granulocyte-macrophage colony-stimulating factor and human erythropoietin for treatment of myelodysplastic syndromes.
Runde V; Aul C; Ebert A; Grabenhorst U; Schneider W
Eur J Haematol; 1995 Jan; 54(1):39-45. PubMed ID: 7859874
[TBL] [Abstract][Full Text] [Related]
34. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin.
Negrin RS; Stein R; Vardiman J; Doherty K; Cornwell J; Krantz S; Greenberg PL
Blood; 1993 Aug; 82(3):737-43. PubMed ID: 7687889
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.
Vannucchi AM; Bosi A; Ieri A; Guidi S; Saccardi R; Lombardini L; Linari S; Laszlo D; Longo G; Rossi-Ferrini P
Bone Marrow Transplant; 1996 Apr; 17(4):527-31. PubMed ID: 8722349
[TBL] [Abstract][Full Text] [Related]
36. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
Mantovani L; Lentini G; Hentschel B; Wickramanayake PD; Loeffler M; Diehl V; Tesch H
Br J Haematol; 2000 May; 109(2):367-75. PubMed ID: 10848827
[TBL] [Abstract][Full Text] [Related]
37. Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietins.
Santini V
Semin Hematol; 2012 Oct; 49(4):295-303. PubMed ID: 23079059
[TBL] [Abstract][Full Text] [Related]
38. The role of erythropoietin in the anemia of myelodysplastic syndrome.
Stein RS
Clin Lymphoma; 2003 Aug; 4 Suppl 1():S36-40. PubMed ID: 14556674
[TBL] [Abstract][Full Text] [Related]
39. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.
Giraldo P; Nomdedeu B; Loscertales J; Requena C; de Paz R; Tormo M; Navarro P; Benedit P; Gasquet JA;
Cancer; 2006 Dec; 107(12):2807-16. PubMed ID: 17115424
[TBL] [Abstract][Full Text] [Related]
40. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]